These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 12671890

  • 1. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.
    Gerbes AL, Gülberg V, Ginès P, Decaux G, Gross P, Gandjini H, Djian J, VPA Study Group.
    Gastroenterology; 2003 Apr; 124(4):933-9. PubMed ID: 12671890
    [Abstract] [Full Text] [Related]

  • 2. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
    Wong F, Blei AT, Blendis LM, Thuluvath PJ.
    Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
    Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D, HypoCAT Study Investigators.
    Hepatology; 2008 Jul; 48(1):204-13. PubMed ID: 18508290
    [Abstract] [Full Text] [Related]

  • 6. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators.
    N Engl J Med; 2006 Nov 16; 355(20):2099-112. PubMed ID: 17105757
    [Abstract] [Full Text] [Related]

  • 7. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH.
    J Hepatol; 2012 Mar 16; 56(3):571-8. PubMed ID: 22027579
    [Abstract] [Full Text] [Related]

  • 8. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan Investigators.
    Circulation; 2003 Jun 03; 107(21):2690-6. PubMed ID: 12742979
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.
    Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P, Minini P, Bernardi M.
    J Hepatol; 2010 Aug 03; 53(2):283-90. PubMed ID: 20541828
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N, Conivaptan Study Group.
    Am J Nephrol; 2007 Aug 03; 27(5):447-57. PubMed ID: 17664863
    [Abstract] [Full Text] [Related]

  • 15. Vaptans: a promising therapy in the management of advanced cirrhosis.
    Ginès P.
    J Hepatol; 2007 Jun 03; 46(6):1150-2. PubMed ID: 17445935
    [Abstract] [Full Text] [Related]

  • 16. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
    Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW.
    J Am Coll Cardiol; 2006 Apr 18; 47(8):1615-21. PubMed ID: 16630999
    [Abstract] [Full Text] [Related]

  • 17. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia.
    Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, Orlandi C, Tolvaptan Investigators.
    Am J Cardiol; 2006 Apr 01; 97(7):1064-7. PubMed ID: 16563917
    [Abstract] [Full Text] [Related]

  • 18. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
    Palm C, Pistrosch F, Herbrig K, Gross P.
    Am J Med; 2006 Jul 01; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
    [Abstract] [Full Text] [Related]

  • 19. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
    Thuluvath PJ, Maheshwari A, Wong F, Yoo HW, Schrier RW, Parikh C, Steare S, Korula J.
    Aliment Pharmacol Ther; 2006 Sep 15; 24(6):973-82. PubMed ID: 16948809
    [Abstract] [Full Text] [Related]

  • 20. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
    Ghali JK, Zmily HD, Farah JO, Daifallah S.
    IDrugs; 2010 Nov 15; 13(11):782-92. PubMed ID: 21046526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.